Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH (tenapanor)

WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH (tenapanor) was presented in a series of poster presentations at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, now underway in Long Beach, California. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.

XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

“We are excited to share this data, as it continues to demonstrate the significant impact XPHOZAH can have for patients with chronic kidney disease on dialysis with serum phosphorus levels above guideline-established levels, as many currently struggle to achieve these goals without a new treatment option,” said David Spiegel, MD, vice president, nephrology at Ardelyx. “Our commitment is to these patients who are living with a life-changing diagnosis, and the data being presented at NKF Spring Clinical Meetings showcases why we believe this treatment will bring advancement and innovation to their care.”

Poster #239, entitled “Tenapanor Treatment Added to Phosphate Binders Improved Long-Term Serum Phosphate (P) Control as Measured by Reduction in Average Daily P Area Under the Curve,” reviewed data from an area under the curve (AUC) assessment meant to provide a more comprehensive evaluation of serum phosphate levels than individual serum phosphate measurements. The assessment found that tenapanor added to sevelamer treatment resulted in improved phosphate control as measured by average daily phosphate AUC in sevelamer-treated patients from the PHREEDOM Phase 3 study who continued into the NORMALIZE open-label extension study.